PMID- 31293422
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 10
DP  - 2019
TI  - Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A 
      Systematic Review and Meta-Analysis of Clinical Trials.
PG  - 697
LID - 10.3389/fphar.2019.00697 [doi]
LID - 697
AB  - Background: B-cell leukemia/lymphoma-2 (BCL-2) protein is an important part of 
      apoptotic pathway, which is overexpressed in chronic lymphocytic leukemia cells, 
      non-Hodgkin lymphoma cells, and myeloma cells. Venetoclax (ABT-199/GDC-0199) is a 
      highly selective bioavailable inhibitor of BCL-2 protein, which is more effective 
      and less valid against BCL-xL in BCL2-dependent leukemia and lymphoma cell. 
      Method: We searched PubMed database using retrieval keyword venetoclax, ABT-199, 
      or GDC-0199 and investigated the data of the involved articles. Considering 
      variability in different studies, the overall response rate was collected to 
      assess the efficacy. Meanwhile, adverse events (AEs) were summarized, and event 
      rates were calculated to assess the safety. Results: When patients were treated 
      with venetoclax monotherapy, the most common AEs were nausea, diarrhea, 
      neutropenia, fatigue and thrombocytopenia, and neutropenia. In addition, 
      thrombocytopenia, anemia, febrile neutropenia, and leukopenia appeared more 
      common and are considered as the severe AEs (defined as grade >/= 3 AEs). Although 
      the occurrence of thrombocytopenia was relatively high, it was not the most 
      severe type. When compared with patients treated with venetoclax and other drugs, 
      nausea, diarrhea, and thrombocytopenia were still the most common AEs occurrence 
      in the patients of all the grade. The overall event rate was 73%, which is quite 
      satisfactory. Conclusion: Venetoclax is a mild and efficient drug in treating 
      advanced hematological malignancy, which can be specially fit for the chronic 
      lymphocytic leukemia patients with del[17p], and AEs are well tolerable. Few 
      tumor lysis syndrome occurred after taking the drugs. The AEs aroused by 
      venetoclax, and the combination is well tolerable. Therefore, the use of 
      venetoclax monotherapy or its combination with other therapies is desirable in 
      hematological malignancy.
FAU - Li, Qingfang
AU  - Li Q
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, Chengdu, China.
FAU - Cheng, Li
AU  - Cheng L
AD  - State Key Laboratory of Oral Diseases & National Clinical Research Center for 
      Oral Diseases & Department of Preventive Dentistry, West China Hospital of 
      Stomatology, Sichuan University, Sichuan, China.
FAU - Shen, Kai
AU  - Shen K
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, Chengdu, China.
FAU - Jin, Hongyu
AU  - Jin H
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, Chengdu, China.
FAU - Li, Hui
AU  - Li H
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, Chengdu, China.
FAU - Cheng, Yuan
AU  - Cheng Y
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, Chengdu, China.
FAU - Ma, Xuelei
AU  - Ma X
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Systematic Review
DEP - 20190621
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6598635
OTO - NOTNLM
OT  - Bcl-2 inhibitor
OT  - chronic lymphocytic leukemia
OT  - deletion of chromosome 17p
OT  - hematological malignancy
OT  - venetoclax
EDAT- 2019/07/12 06:00
MHDA- 2019/07/12 06:01
PMCR- 2019/06/21
CRDT- 2019/07/12 06:00
PHST- 2019/03/26 00:00 [received]
PHST- 2019/05/29 00:00 [accepted]
PHST- 2019/07/12 06:00 [entrez]
PHST- 2019/07/12 06:00 [pubmed]
PHST- 2019/07/12 06:01 [medline]
PHST- 2019/06/21 00:00 [pmc-release]
AID - 10.3389/fphar.2019.00697 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Jun 21;10:697. doi: 10.3389/fphar.2019.00697. eCollection 
      2019.